Screening for opioid use disorder and co-occurring depression and post-traumatic stress disorder in primary care in New Mexico.
Depression
Mental health
Opioid use disorder
Post-traumatic stress disorder
Primary care
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
27 01 2023
27 01 2023
Historique:
received:
24
06
2022
accepted:
18
01
2023
entrez:
28
1
2023
pubmed:
29
1
2023
medline:
1
2
2023
Statut:
epublish
Résumé
Identifying patients in primary care services with opioid use disorder and co-occurring mental health disorders is critical to providing treatment. Objectives of this study were to (1) assess the feasibility of recruiting people to screen in-person for opioid use disorder and co-occurring mental health disorders (depression and/or post-traumatic stress disorder) in primary care clinic waiting rooms in preparation for a randomized controlled trial, and (2) compare results of detecting these disorders by universal in-person screening compared to electronic health record (EHR) diagnoses. This cross-sectional feasibility and pilot study recruited participants from four primary care clinics, two rural and two urban, from three health care organizations in New Mexico. Inclusion criteria were adults (≥ 18 years), attending one of the four clinics as a patient, and who spoke English or Spanish. Exclusion criteria were people attending the clinic for a non-primary care visit (e.g., dental, prescription pick up, social support). The main outcomes and measures were (1) recruitment feasibility which was assessed by frequencies and proportions of people approached and consented for in-person screening, and (2) relative differences of detecting opioid use disorder and co-occurring mental health disorders in waiting rooms relative to aggregate EHR data from each clinic, measured by prevalence and prevalence ratios. Over two-weeks, 1478 potential participants were approached and 1145 were consented and screened (77.5% of patients approached). Probable opioid use disorder and co-occurring mental health disorders were identified in 2.4% of those screened compared to 0.8% in EHR. Similarly, universal screening relative to EHR identified higher proportions of probable opioid use disorder (4.5% vs. 3.4%), depression (17.5% vs. 12.7%) and post-traumatic stress disorder (19.0% vs. 3.6%). Universal screening for opioid use disorder, depression, and post-traumatic stress disorder was feasible, and identified three times as many patients with these co-occurring disorders compared to EHR. Higher proportions of each condition were also identified, especially post-traumatic stress disorder. Results support that there are likely gaps in identification of these disorders in primary care services and demonstrate the need to better address the persistent public health problem of these co-occurring disorders.
Sections du résumé
BACKGROUND
Identifying patients in primary care services with opioid use disorder and co-occurring mental health disorders is critical to providing treatment. Objectives of this study were to (1) assess the feasibility of recruiting people to screen in-person for opioid use disorder and co-occurring mental health disorders (depression and/or post-traumatic stress disorder) in primary care clinic waiting rooms in preparation for a randomized controlled trial, and (2) compare results of detecting these disorders by universal in-person screening compared to electronic health record (EHR) diagnoses.
METHODS
This cross-sectional feasibility and pilot study recruited participants from four primary care clinics, two rural and two urban, from three health care organizations in New Mexico. Inclusion criteria were adults (≥ 18 years), attending one of the four clinics as a patient, and who spoke English or Spanish. Exclusion criteria were people attending the clinic for a non-primary care visit (e.g., dental, prescription pick up, social support). The main outcomes and measures were (1) recruitment feasibility which was assessed by frequencies and proportions of people approached and consented for in-person screening, and (2) relative differences of detecting opioid use disorder and co-occurring mental health disorders in waiting rooms relative to aggregate EHR data from each clinic, measured by prevalence and prevalence ratios.
RESULTS
Over two-weeks, 1478 potential participants were approached and 1145 were consented and screened (77.5% of patients approached). Probable opioid use disorder and co-occurring mental health disorders were identified in 2.4% of those screened compared to 0.8% in EHR. Similarly, universal screening relative to EHR identified higher proportions of probable opioid use disorder (4.5% vs. 3.4%), depression (17.5% vs. 12.7%) and post-traumatic stress disorder (19.0% vs. 3.6%).
CONCLUSIONS
Universal screening for opioid use disorder, depression, and post-traumatic stress disorder was feasible, and identified three times as many patients with these co-occurring disorders compared to EHR. Higher proportions of each condition were also identified, especially post-traumatic stress disorder. Results support that there are likely gaps in identification of these disorders in primary care services and demonstrate the need to better address the persistent public health problem of these co-occurring disorders.
Identifiants
pubmed: 36707910
doi: 10.1186/s13722-023-00362-5
pii: 10.1186/s13722-023-00362-5
pmc: PMC9881516
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Subventions
Organisme : NIMH NIH HHS
ID : UF1 MH121954
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Nord J Psychiatry. 2018 Sep;72(sup1):S20-S22
pubmed: 30489215
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720932017
pubmed: 32507067
J Racial Ethn Health Disparities. 2016 Dec;3(4):692-705
pubmed: 27294764
Arch Gen Psychiatry. 2007 May;64(5):566-76
pubmed: 17485608
Arch Gen Psychiatry. 2005 Jun;62(6):617-27
pubmed: 15939839
J Clin Psychol Med Settings. 2011 Sep;18(3):268-80
pubmed: 21512750
N Engl J Med. 2005 Jun 16;352(24):2515-23
pubmed: 15958807
Clin Psychol Rev. 2015 Jun;38:25-38
pubmed: 25792193
Drug Alcohol Depend. 2020 Feb 1;207:107732
pubmed: 31835068
Drug Alcohol Depend. 2013 Sep 1;132(1-2):95-100
pubmed: 23410617
Ann Emerg Med. 2022 Feb;79(2):158-167
pubmed: 34119326
Am J Psychiatry. 2012 Aug;169(8):790-804
pubmed: 22772364
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Gen Hosp Psychiatry. 2005 Nov-Dec;27(6):392-9
pubmed: 16271653
J Trauma Stress. 2000 Jan;13(1):57-75
pubmed: 10761174
Psychol Med. 2015 Jan;45(1):11-27
pubmed: 24569086
Br J Gen Pract. 2008 Oct;58(555):694-8
pubmed: 18826781
J Addict Dis. 2013;32(2):168-79
pubmed: 23815424
Contemp Clin Trials. 2021 May;104:106354
pubmed: 33713840
J Gen Intern Med. 2007 Jun;22(6):719-26
pubmed: 17503105
JAMA Psychiatry. 2021 Apr 1;78(4):372-379
pubmed: 33533876
Lancet. 2019 Apr 27;393(10182):1760-1772
pubmed: 30878228
Evid Based Med. 2016 Dec;21(6):214-221
pubmed: 27836921
Ann Fam Med. 2011 Sep-Oct;9(5):439-46
pubmed: 21911763
JAMA Netw Open. 2021 May 3;4(5):e2110721
pubmed: 34014326
J Gen Intern Med. 2016 Oct;31(10):1206-11
pubmed: 27170304
Subst Abuse Treat Prev Policy. 2020 Mar 16;15(1):22
pubmed: 32178693
N Engl J Med. 2016 Jan 14;374(2):154-63
pubmed: 26760086
J Gen Intern Med. 2016 May;31(5):509-17
pubmed: 26850413
Harv Rev Psychiatry. 2018 Nov/Dec;26(6):352-363
pubmed: 30407234
Addict Sci Clin Pract. 2019 Oct 15;14(1):39
pubmed: 31615549
J Subst Abuse Treat. 2020 Mar;110:18-27
pubmed: 31952624
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1049-1057
pubmed: 32790653
J Addict Med. 2016 Nov/Dec;10(6):387-394
pubmed: 27753718
J Gen Intern Med. 2018 Mar;33(3):335-346
pubmed: 28948432
JAMA. 2016 Jan 26;315(4):380-7
pubmed: 26813211
PLoS One. 2014 Sep 29;9(9):e108114
pubmed: 25264616
Public Health Rep. 2019 Sep/Oct;134(5):456-460
pubmed: 31390301
Subst Abus. 2022;43(1):240-244
pubmed: 34086531
Gen Hosp Psychiatry. 2005 May-Jun;27(3):169-79
pubmed: 15882763
Ann Fam Med. 2014 Mar-Apr;12(2):128-33
pubmed: 24615308
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
JAMA Intern Med. 2017 Oct 1;177(10):1480-1488
pubmed: 28846769
Gen Hosp Psychiatry. 2000 Jul-Aug;22(4):261-9
pubmed: 10936633
Psychol Trauma. 2018 Nov;10(6):636-642
pubmed: 28758767
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
JAMA. 2020 Jun 9;323(22):2263-2265
pubmed: 32515804
Psychol Trauma. 2011 Jun;3(2):101-108
pubmed: 21765966
Harv Rev Psychiatry. 2017 Jul/Aug;25(4):159-169
pubmed: 28557811
Ann Intern Med. 2009 Dec 1;151(11):793-803
pubmed: 19949145
Health Aff (Millwood). 2017 Oct 1;36(10):1739-1747
pubmed: 28971918
Ann Intern Med. 2015 Aug 18;163(4):298-9
pubmed: 26121401
PLoS One. 2015 May 28;10(5):e0126529
pubmed: 26020791
Patient Educ Couns. 2011 Feb;82(2):207-13
pubmed: 20570462
Arch Gen Psychiatry. 2004 Jul;61(7):714-9
pubmed: 15237083
Health Psychol. 2000 Jan;19(1):91-7
pubmed: 10711592
Drug Alcohol Depend. 2016 Sep 01;166:26-31
pubmed: 27422763